<unk>  is a vaccine used to prevent<unk>  fever in humans. Development of<unk> s began in the 1920s, but was hindered by the need to create immunity against all four<unk>  serotypes. As of 2021, one version is commercially available, known as CYD-TDV, and sold under the brand name Dengvaxia. The vaccine is only recommended in those who have previously had<unk>  fever or populations in which most people have been previously infected. The value of the vaccine is limited by the fact that it may increase the risk of severe<unk>  in those who have not previously been infected. In 2017, more than 733,000 children and more than 50,000 adult volunteers were vaccinated with CYD-TDV regardless of serostatus, which led to a controversy. In March 2021, the European Medicines Agency accepted the filing package for vaccine candidate TAK-003, which is designated for people not previously infected. There are several other vaccine candidates in development including live attenuated, inactivated, DNA and subunit vaccines.
Dengue vaccine
Malaria vaccine
Rabies vaccine
Ebola vaccine
Hantavirus vaccine
Yellow fever vaccine
Brucellosis vaccine
Japanese encephalitis vaccine